We provide you with 20 years of free, institutional-grade data for SAGE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SAGE. Explore the full financial landscape of SAGE stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-07-30 | 1597553 | SAGE | 10-Q | Url |
| 2025-04-29 | 1597553 | SAGE | 10-Q | Url |
| 2025-02-11 | 1597553 | SAGE | 10-K | Url |
| 2024-10-29 | 1597553 | SAGE | 10-Q | Url |
| 2024-07-31 | 1597553 | SAGE | 10-Q | Url |
| 2024-04-25 | 1597553 | SAGE | 10-Q | Url |
| 2024-02-14 | 1597553 | SAGE | 10-K | Url |
| 2023-11-07 | 1597553 | SAGE | 10-Q | Url |
| 2023-08-07 | 1597553 | SAGE | 10-Q | Url |
| 2023-05-02 | 1597553 | SAGE | 10-Q | Url |
| 2023-02-16 | 1597553 | SAGE | 10-K | Url |
| 2022-11-08 | 1597553 | SAGE | 10-Q | Url |
| 2022-08-02 | 1597553 | SAGE | 10-Q | Url |
| 2022-05-03 | 1597553 | SAGE | 10-Q | Url |
| 2022-02-24 | 1597553 | SAGE | 10-K | Url |
| 2021-11-02 | 1597553 | SAGE | 10-Q | Url |
| 2021-08-03 | 1597553 | SAGE | 10-Q | Url |
| 2021-05-04 | 1597553 | SAGE | 10-Q | Url |
| 2021-02-24 | 1597553 | SAGE | 10-K | Url |
| 2020-11-05 | 1597553 | SAGE | 10-Q | Url |
| 2020-08-10 | 1597553 | SAGE | 10-Q | Url |
| 2020-05-07 | 1597553 | SAGE | 10-Q | Url |
| 2020-02-27 | 1597553 | SAGE | 10-K | Url |
| 2019-11-12 | 1597553 | SAGE | 10-Q | Url |
| 2019-08-06 | 1597553 | SAGE | 10-Q | Url |
| 2019-05-02 | 1597553 | SAGE | 10-Q | Url |
| 2019-02-19 | 1597553 | SAGE | 10-K | Url |
| 2018-11-06 | 1597553 | SAGE | 10-Q | Url |
| 2018-08-07 | 1597553 | SAGE | 10-Q | Url |
| 2018-05-03 | 1597553 | SAGE | 10-Q | Url |
| 2018-02-22 | 1597553 | SAGE | 10-K | Url |
| 2017-11-02 | 1597553 | SAGE | 10-Q | Url |
| 2017-08-03 | 1597553 | SAGE | 10-Q | Url |
| 2017-05-10 | 1597553 | SAGE | 10-Q | Url |
| 2017-02-24 | 1597553 | SAGE | 10-K | Url |
| 2016-11-03 | 1597553 | SAGE | 10-Q | Url |
| 2016-08-09 | 1597553 | SAGE | 10-Q | Url |
| 2016-05-06 | 1597553 | SAGE | 10-Q | Url |
| 2016-02-29 | 1597553 | SAGE | 10-K | Url |
| 2015-11-06 | 1597553 | SAGE | 10-Q | Url |
| 2015-08-12 | 1597553 | SAGE | 10-Q | Url |
| 2015-05-15 | 1597553 | SAGE | 10-Q | Url |
| 2015-04-07 | 1597553 | SAGE | S-1 | Url |
| 2015-03-06 | 1597553 | SAGE | 10-K | Url |
| 2014-11-13 | 1597553 | SAGE | 10-Q | Url |
| 2014-08-14 | 1597553 | SAGE | 10-Q | Url |
| 2014-06-17 | 1597553 | SAGE | S-1 | Url |
Sage Therapeutics, Inc(NASDAQ:SAGE) 
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product p...
Website: http://www.sagerx.com
Founded: 2010
Full Time Employees: 675
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about SAGE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.